Information Provided By:
Fly News Breaks for December 8, 2017
KPTI
Dec 8, 2017 | 06:51 EDT
JPMorgan analyst Eric Joseph raised his price target for Karyopharm Therapeutics to $18 from $16 ahead of the this weekend's American Society of Hematology conference. Focus for the stock remains on data from the pivotal Phase 2 Storm expansion cohort of selinexor in penta-refractory multiple myeloma, Joseph tells investors in a research note. Based on prior Phase 2 results, the analyst believes the clinical profile of selinexor is de-risked. He sees a high likelihood of Storm repeating approval level activity in a "high unmet need patient population." Joseph keeps an Overweight rating on Karyopharm.
News For KPTI From the Last 2 Days
There are no results for your query KPTI